Sarkar, Subhashis
Chauhan, Sachin K. S.
Daly, John
Natoni, Alessandro
Fairfield, Heather
Henderson, Robert
Nolan, Emma
Swan, Dawn
Hu, Jinsong
Reagan, Michaela R.
O’Dwyer, Michael http://orcid.org/0000-0002-6173-7140
Funding for this research was provided by:
ONK Therapeutics (ONK Therapeutics)
National Institutes of Health (P20GM121301)
American Cancer Society (RSG-19-037-01-LIB)
Article History
Received: 30 June 2019
Accepted: 31 December 2019
First Online: 9 January 2020
Compliance with ethical standards
:
: Subhashis Sarkar: ONK Therapeutics Ltd.: Research funding; Michael O'Dwyer: Abbvie: Membership on advisory committee; Celgene: Membership on advisory committee, and research funding; Bristol Myers Squibb (BMS): Research funding; Glycomimetics: Research funding; ONK Therapeutics Ltd.: Equity Ownership, Membership on Board of Directors, and research funding; Janssen: Membership on advisory committees, and research funding; Michaela R. Reagan: ONK Therapeutics Ltd.: Research funding. A provisional patent application was filed by Subhashis Sarkar and Michael O'Dwyer regarding the CD16 work described in the paper. All other authors declare no conflict of interest.
: All experiments utilizing primary cells from MM patients were conducted in accordance with the ethical standards of the Clinical Research Ethics Committee University Hospital Galway and the 1964 Declaration of Helsinki. The collection of bone marrow samples from MM patients was approved by Clinical Research Ethics Committee University Hospital Galway on June 14, 2017 (Study no. C.A.1519) All experiments utilizing blood samples from healthy donors were conducted in accordance with the ethical standards of the Clinical Research Ethics Committee University Hospital Galway and the 1964 Declaration of Helsinki. The collection of blood samples from healthy volunteers was approved by Clinical Research Ethics Committee University Hospital Galway on August 4, 2017 (Study no. C.A.1805) Animal research experiments to examine in vivo bone marrow homing were performed at the Maine Medical Center Research Institute with approval from the institutional animal care and use committee (IACUC); (Protocol #MR1508), an (Association for assessment and accrediation of laboratory animal care) AAALAC international accredited program. Approval for the experiments in this manuscript was issued by the Maine Medical Center Research Institute (MMCRI) Institutional Animal care and use committee (IACUC) on September 2, 2016.
: NK cells were freshly isolated from peripheral blood samples of anonymous volunteer healthy donors at the University Hospital Galway, Ireland. Oral informed consent was obtained from all blood donors to the use of their blood for scientific purposes. Bone Marrow samples were provided by the Haematology Unit of University Hospital Galway, Galway from MM patients who had provided written consent for remaining samples to be used for immunology related research.
: Female NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ mice (Stock# 005557) were purchased at 4-weeks of age from Jackson Laboratory (Bar Harbor, ME) and acclimated at the Maine Medical Center Research Institute animal facility for at least two weeks prior being randomly assigned to each group for experiments.
: KHYG1 was a kind gift from Dr. Armand Keating, University of Toronto (Canada) and the cell line was authenticated by STR profiling on 06/06/2017. MM1S, RPMI-8226, JJN3, H929, and U266, were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). NK-92 was purchased from Deutsche Sammlung von Mikcroorganismen and Zellkulturen (DSMZ) (Braunschweig, Germany) The cell lines were initially grown and cryopreserved into multiple aliquots of master cell bank (MCB). All the experiments were performed with cells at low passage numbers (≤ 10). Mycoplasma was routinely tested.